• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
CRS-MIS in Candida glabrata: sphingolipids modulate echinocandin-Fks interaction.光滑念珠菌中的 CRS-MIS:鞘脂类调节棘白菌素-Fks 相互作用。
Mol Microbiol. 2012 Oct;86(2):303-13. doi: 10.1111/j.1365-2958.2012.08194.x. Epub 2012 Aug 22.
2
Candida glabrata mutants demonstrating paradoxical reduced caspofungin susceptibility but increased micafungin susceptibility.表现出矛盾性降低卡泊芬净敏感性但增加米卡芬净敏感性的光滑念珠菌突变体。
Antimicrob Agents Chemother. 2011 Aug;55(8):3947-9. doi: 10.1128/AAC.00044-11. Epub 2011 May 31.
3
Evolutionary dynamics in gut-colonizing Candida glabrata during caspofungin therapy: Emergence of clinically important mutations in sphingolipid biosynthesis.肠道定植性光滑念珠菌在卡泊芬净治疗期间的进化动态:鞘脂生物合成中出现临床上重要的突变。
PLoS Pathog. 2024 Sep 9;20(9):e1012521. doi: 10.1371/journal.ppat.1012521. eCollection 2024 Sep.
4
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.棘白菌素类耐药性在光滑念珠菌中的增加:临床失败与 FKS 突变和最低抑菌浓度升高相关。
Clin Infect Dis. 2013 Jun;56(12):1724-32. doi: 10.1093/cid/cit136. Epub 2013 Mar 13.
5
Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.通过体内药效学评估优化棘白菌素类药物剂量和敏感性折点判断方法,用于治疗有或无 fks 突变的光滑念珠菌感染。
Antimicrob Agents Chemother. 2012 Nov;56(11):5875-82. doi: 10.1128/AAC.01102-12. Epub 2012 Sep 4.
6
Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance.Fks1 和 Fks2 在 Candida glabrata 中具有功能冗余性,但受到差异调节:对棘白菌素类耐药性的影响。
Antimicrob Agents Chemother. 2012 Dec;56(12):6304-9. doi: 10.1128/AAC.00813-12. Epub 2012 Oct 1.
7
Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates.米卡芬净、卡泊芬净和伏立康唑对野生型和FKS突变型光滑念珠菌分离株的固有炎症反应及免疫药理活性
Antimicrob Agents Chemother. 2015 Sep;59(9):5405-12. doi: 10.1128/AAC.00624-15. Epub 2015 Jun 22.
8
Spontaneous Mutational Frequency and Mutation Rates Vary by Echinocandin Agent against .棘白菌素类药物对. 的自发突变频率和突变率各不相同。
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01692-18. Print 2019 Jan.
9
Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.FKS突变在光滑念珠菌中的作用:最低抑菌浓度值、棘白菌素耐药性和多重耐药性。
Antimicrob Agents Chemother. 2014 Aug;58(8):4690-6. doi: 10.1128/AAC.03255-14. Epub 2014 Jun 2.
10
Reconstitution of high-level micafungin resistance detected in a clinical isolate of Candida glabrata identifies functional homozygosity in glucan synthase gene expression.在光滑念珠菌临床分离株中检测到的高水平米卡芬净耐药性的重建,确定了葡聚糖合酶基因表达中的功能性纯合性。
J Antimicrob Chemother. 2012 Jul;67(7):1666-76. doi: 10.1093/jac/dks112. Epub 2012 Apr 18.

引用本文的文献

1
Tn-seq screens in treated with echinocandins and ibrexafungerp reveal pathways of antifungal resistance and cross-resistance.用棘白菌素和ibrexafungerp处理后的Tn-seq筛选揭示了抗真菌耐药性和交叉耐药性的途径。
mSphere. 2025 Jul 29;10(7):e0027025. doi: 10.1128/msphere.00270-25. Epub 2025 Jul 7.
2
Improved Broad Spectrum Antifungal Drug Synergies with Cryptomycin, a Cdc50-Inspired Antifungal Peptide.增强广谱抗真菌药物协同作用的 Cryptomycin,一种受 Cdc50 启发的抗真菌肽。
ACS Infect Dis. 2024 Nov 8;10(11):3973-3993. doi: 10.1021/acsinfecdis.4c00681. Epub 2024 Oct 29.
3
Evolutionary dynamics in gut-colonizing Candida glabrata during caspofungin therapy: Emergence of clinically important mutations in sphingolipid biosynthesis.肠道定植性光滑念珠菌在卡泊芬净治疗期间的进化动态:鞘脂生物合成中出现临床上重要的突变。
PLoS Pathog. 2024 Sep 9;20(9):e1012521. doi: 10.1371/journal.ppat.1012521. eCollection 2024 Sep.
4
Calcineurin-dependent contributions to fitness in the opportunistic pathogen .钙调神经磷酸酶依赖性对机会性病原体适应性的贡献。
mSphere. 2024 Jan 30;9(1):e0055423. doi: 10.1128/msphere.00554-23. Epub 2024 Jan 3.
5
Lipid-Centric Approaches in Combating Infectious Diseases: Antibacterials, Antifungals and Antivirals with Lipid-Associated Mechanisms of Action.以脂质为中心的传染病防治方法:具有脂质相关作用机制的抗菌、抗真菌和抗病毒药物。
Antibiotics (Basel). 2023 Dec 11;12(12):1716. doi: 10.3390/antibiotics12121716.
6
Whole genome analysis of echinocandin non-susceptible Candida Glabrata clinical isolates: a multi-center study in China.棘白菌素类药物不敏感近平滑念珠菌临床分离株的全基因组分析:中国多中心研究。
BMC Microbiol. 2023 Nov 16;23(1):341. doi: 10.1186/s12866-023-03105-3.
7
Structural and mechanistic insights into fungal β-1,3-glucan synthase FKS1.真菌β-1,3-葡聚糖合成酶 FKS1 的结构和机制见解。
Nature. 2023 Apr;616(7955):190-198. doi: 10.1038/s41586-023-05856-5. Epub 2023 Mar 22.
8
Serine/Threonine Phosphatase Calcineurin Orchestrates the Intrinsic Resistance to Micafungin in the Human-Pathogenic Fungus Mucor circinelloides.丝氨酸/苏氨酸磷酸酶钙调神经磷酸酶调控人致病真菌环孢菌对米卡芬净的固有耐药性。
Antimicrob Agents Chemother. 2023 Feb 16;67(2):e0068622. doi: 10.1128/aac.00686-22. Epub 2023 Jan 23.
9
Strains Adapted to Caspofungin Due to Aneuploidy Become Highly Tolerant under Continued Drug Pressure.由于非整倍体而适应卡泊芬净的菌株在持续的药物压力下变得高度耐受。
Microorganisms. 2022 Dec 21;11(1):23. doi: 10.3390/microorganisms11010023.
10
Echinocandin Resistance in Has Broad Implications for Membrane Lipid Perturbations That Influence Drug-Target Interactions.棘白菌素耐药性对影响药物-靶点相互作用的膜脂质扰动具有广泛影响。
Microbiol Insights. 2019 Dec 31;12:1178636119897034. doi: 10.1177/1178636119897034. eCollection 2019.

本文引用的文献

1
Topological and mutational analysis of Saccharomyces cerevisiae Fks1.酿酒酵母Fks1的拓扑结构与突变分析
Eukaryot Cell. 2012 Jul;11(7):952-60. doi: 10.1128/EC.00082-12. Epub 2012 May 11.
2
Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance.棘白菌素耐药相关的白念珠菌 FKS1 热点突变的适应性和毒力代价。
J Infect Dis. 2011 Aug 15;204(4):626-35. doi: 10.1093/infdis/jir351.
3
Candida glabrata mutants demonstrating paradoxical reduced caspofungin susceptibility but increased micafungin susceptibility.表现出矛盾性降低卡泊芬净敏感性但增加米卡芬净敏感性的光滑念珠菌突变体。
Antimicrob Agents Chemother. 2011 Aug;55(8):3947-9. doi: 10.1128/AAC.00044-11. Epub 2011 May 31.
4
Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin.利用流行病学截断值来检测 9 年来念珠菌属对安尼鲁单抗、卡泊芬净和米卡芬净敏感性的变化趋势。
J Clin Microbiol. 2011 Feb;49(2):624-9. doi: 10.1128/JCM.02120-10. Epub 2010 Dec 8.
5
Roles for sphingolipids in Saccharomyces cerevisiae.鞘脂类在酿酒酵母中的作用。
Adv Exp Med Biol. 2010;688:217-31. doi: 10.1007/978-1-4419-6741-1_15.
6
Sphingolipid analysis by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS).高效液相色谱-串联质谱法(HPLC-MS/MS)分析神经鞘脂。
Adv Exp Med Biol. 2010;688:46-59. doi: 10.1007/978-1-4419-6741-1_3.
7
FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.FKS 突变与美国基于人群监测的光滑念珠菌分离株中棘白菌素 MIC 值升高相关。
Antimicrob Agents Chemother. 2010 Dec;54(12):5042-7. doi: 10.1128/AAC.00836-10. Epub 2010 Sep 13.
8
Breakthrough invasive candidiasis in patients on micafungin.米卡芬净治疗患者发生突破性侵袭性念珠菌病。
J Clin Microbiol. 2010 Jul;48(7):2373-80. doi: 10.1128/JCM.02390-09. Epub 2010 Apr 26.
9
Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains.全球范围内念珠菌菌株的 fks1 热点 1 突变低流行率。
Antimicrob Agents Chemother. 2010 Jun;54(6):2655-9. doi: 10.1128/AAC.01711-09. Epub 2010 Apr 5.
10
Novel FKS mutations associated with echinocandin resistance in Candida species.新型 FKS 突变与棘白菌素类耐药的念珠菌属相关。
Antimicrob Agents Chemother. 2010 May;54(5):2225-7. doi: 10.1128/AAC.00998-09. Epub 2010 Feb 9.

光滑念珠菌中的 CRS-MIS:鞘脂类调节棘白菌素-Fks 相互作用。

CRS-MIS in Candida glabrata: sphingolipids modulate echinocandin-Fks interaction.

机构信息

Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA 19129, USA.

出版信息

Mol Microbiol. 2012 Oct;86(2):303-13. doi: 10.1111/j.1365-2958.2012.08194.x. Epub 2012 Aug 22.

DOI:10.1111/j.1365-2958.2012.08194.x
PMID:22909030
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3472958/
Abstract

Infections with the azole-refractory yeast Candida glabrata are now commonly treated with the echinocandins caspofungin (CSF) or micafungin (MCF). True resistance (>  32-fold decreased susceptibility) to these lipopeptide inhibitors of cell wall synthesis is rare and strictly associated with mutations in integral membrane proteins Fks1 or Fks2. In contrast, mutants exhibiting 4- to 32-fold CSF reduced susceptibility (CRS) were readily selected in vitro, and surprisingly demonstrated 4- to 32-fold MCF increased susceptibility (MIS). Sequencing and gene deletion demonstrated that CRS-MIS is Fks-independent. To explore alternative mechanisms, we initially employed Saccharomyces cerevisiae, and observed that CRS was conferred by multiple mutations (fen1Δ, sur4Δ, cka2Δ and tsc10-ts) disrupting sphingolipid biosynthesis. Following this lead, C. glabrata fen1Δ and cka2Δ deletants were constructed, and shown to exhibit CRS-MIS. Sphingolipid analysis of CRS-MIS laboratory mutants and clinical isolates demonstrated elevated dihydrosphingosine (DHS) and phytosphingosine (PHS) levels, and consistent with this sequencing revealed fen1, sur4, ifa38 and sur2 mutations. Moreover, exogenous DHS or PHS conferred a CRS-MIS phenotype on wild-type C. glabrata. Exogenous PHS failed, however, to suppress CRS-MIS in a sur2 mutant blocked in conversion of DHS to PHS, implying that accumulation of these intermediates confers CRS-MIS. We conclude that membrane sphingolipids modulate echinocandin-Fks interaction.

摘要

现在,对于耐唑类的光滑假丝酵母(Candida glabrata)感染,通常采用棘白菌素类药物(如卡泊芬净(CSF)或米卡芬净(MCF))进行治疗。这些细胞壁合成抑制剂的真正耐药性(对药物的敏感性降低 32 倍以上)非常罕见,并且与细胞膜蛋白 Fks1 或 Fks2 的突变密切相关。相比之下,体外很容易筛选出对 CSF 敏感性降低 4-32 倍的突变体(CRS),并且出人意料的是,这些突变体对 MCF 的敏感性增加了 4-32 倍(MIS)。测序和基因缺失表明 CRS-MIS 与 Fks 无关。为了探索替代机制,我们最初使用酿酒酵母(Saccharomyces cerevisiae)进行研究,发现 CRS 是由多个突变(fen1Δ、sur4Δ、cka2Δ 和 tsc10-ts)引起的,这些突变破坏了鞘脂生物合成。在此基础上,构建了 C. glabrata fen1Δ 和 cka2Δ 缺失突变体,并发现它们表现出 CRS-MIS。对 CRS-MIS 实验室突变体和临床分离株的鞘脂分析表明,二氢神经酰胺(DHS)和植物神经酰胺(PHS)水平升高,测序结果也表明存在 fen1、sur4、ifa38 和 sur2 突变。此外,外源性 DHS 或 PHS 可使野生型 C. glabrata 获得 CRS-MIS 表型。然而,在 DHS 向 PHS 转化受阻的 sur2 突变体中,外源性 PHS 未能抑制 CRS-MIS,这意味着这些中间产物的积累赋予了 CRS-MIS 表型。我们的结论是,膜鞘脂调节棘白菌素类药物与 Fks 的相互作用。